I have run thru most of Favipiravir occurrence on
Post# of 72440
I've seen nothing related to Favipiravir given intravenously in any of these many trials. It's all oral delivery.
Don't understand why there is discussion here and on the other board that Favipiravir was speculatively quite prevalent in the Russian sites for the Phase 2.
Did they formulate Favipiravir late last year or early this year to an iv form and hence the minimal 2 month delay for the B+SOC trial??
Anyone see anything about Favipiravir on the European clinical trial site being delivered intravenously??